Founded in by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The past 18 months haven't been very pleasant for biotech investors.

Many individual biotech stocks have performed far worse. One bright side to all of that selling is that a handful of high-quality biotech stocks are currently trading for attractive prices.

With that in mind, here's a look at three biotech stocks that I think are well positioned to outperform in the new year.

Biotech giant Celgene NASDAQ: CELG may be down from its high, but it has held up much better than its large-cap peers.

Top 10 Pharmaceutical Penny Stocks List

That's owed to the company's ability to consistently put up great numbers. Celgene recently provided investors with a sneak peak at its fourth-quarter results that suggest that trend remains intact.

With shares trading around 16 times forward earnings, Celgene offers investors a lower-risk way to buy into the crazy world of biotech. REGN is a former biotech darling that has gone through a bit of a rough patch.

Given the slew of negativity, it is easy to understand why shares have been on the decline. Thankfully, shareholders like me have a few reasons to believe that things are looking up in First, Regeneron and Sanofi will hear from the FDA in March about their new eczema drug candidate, Dupixent. This drug is believed to hold blockbuster potential, so an approval would go a long way toward rebuilding investor confidence. Second, the FDA has recently cleared Sanofi's facility in France that caused the initial rejection of sarilumab.

That means that a resubmission will be on the way soon. The final stock on today's list is Acadia Pharmaceuticals NASDAQ: Sales blew past analysts' expectations in its first full quarter on the market, which hints that there is a lot of pent-up demand for the drug. Looking ahead, promises to be a banner year for the company. If Nuplazid can ultimately snag a label expansion claim in one of these other disease states, then its peak sales could get big in a hurry.

While Acadia is a high-risk bet since it's still burning through capital, the company looks well positioned to surprise to the upside in Brian Feroldi owns shares of Celgene and Regeneron Pharmaceuticals. The Motley Fool owns shares of and recommends Celgene.

The Motley Fool has a disclosure policy. Foolish investor Brian Feroldi has been covering the healthcare industry for the Motley Fool since Brian's investing goal is to buy the highest quality companies that he can find and then let compounding work its magic. See all of his articles here and make sure you follow him on Twitter. Skip to main content The Motley Fool Fool.

Premium Advice Help Fool Answers Contact Us Login.

You are being redirected

Latest Stock Picks Stocks Premium Services. Stock Advisor Flagship service.

Rule Breakers High-growth stocks. Income Investor Dividend stocks.

Hidden Gems Small-cap stocks. Inside Value Undervalued stocks. Learn How to Invest. Credit Cards Best Credit Cards of Best Credit Card Sign-Up Bonuses Best Balance-Transfer Credit Cards Best Travel Credit Cards Best Cash-Back Credit Cards Best No-Annual-Fee Credit Cards Best Small Business Credit Cards. Mortgages Compare Mortgage Rates Get Pre-Approved How Much House Can I Afford?

Taxes How to Reduce Your Taxes Deductions Even Pros Overlook Audit-Proof Your Tax Return What Info Should I Keep? Helping the World Invest — Better. How to Invest Learn How to Invest.

10 Best Biotech Stocks for - Top Stocks - TheStreet Ratings

Personal Finance Credit Cards Best Credit Cards of Best Credit Card Sign-Up Bonuses Best Balance-Transfer Credit Cards Best Travel Credit Cards Best Cash-Back Credit Cards Best No-Annual-Fee Credit Cards Best Small Business Credit Cards.

Jan 22, at 2: Prev 1 2 3 4 Next. Motley Fool push notifications are finally here Allow push notifications to help you stay on top of Breaking investing news Earnings coverage Market movers Special offers and more Subscribe to notifications You can unsubscribe at any time.